Fresenius Medical Care AG has announced a strategic collaboration involving its third-party clinical research organization, Frenova, alongside Nephronomics and GENEWIZ by Azenta Life Sciences. This collaboration is part of the My Reason® genomics research program, which focuses on advancing genomic analysis for the better understanding of kidney, cardiovascular, and metabolic diseases. The collaboration aims to leverage advanced genomic sequencing and analysis to enhance precision medicine in kidney disease care, as well as to develop novel therapies and diagnostics. The My Reason® dataset, noted for its comprehensive data on end-stage kidney disease, is central to this initiative. Through this collaboration, Nephronomics seeks to utilize artificial intelligence and machine learning models to identify new disease subtypes and therapeutic targets. The results of this collaboration have not yet been presented but are expected to contribute significantly to advancements in precision medicine for patients globally.